TCGA-K4-A6FZ-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 1.806833114
- os_event
- false
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.650
- INTERFERON_ALPHA_RESPONSE+0.630
- INTERFERON_GAMMA_RESPONSE+0.580
- INFLAMMATORY_RESPONSE+0.570
- IL6_JAK_STAT3_SIGNALING+0.550
- TGF_BETA_SIGNALING+0.470
- ANDROGEN_RESPONSE+0.440
- PROTEIN_SECRETION+0.440
- APOPTOSIS+0.430
- ALLOGRAFT_REJECTION+0.420
Top 10 suppressed
- MYOGENESIS-0.270
- SPERMATOGENESIS-0.170
- PANCREAS_BETA_CELLS-0.160
- OXIDATIVE_PHOSPHORYLATION-0.120
- BILE_ACID_METABOLISM-0.100
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.090
- DNA_REPAIR-0.070
- E2F_TARGETS-0.060
- KRAS_SIGNALING_DN-0.040
- PEROXISOME-0.020
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | CB1F8B9C-7CE7-4181-B746-7FC697ED27F4 | — | — | 0.891 |
| 2 | TCGA-BA-5556-01A-01R-1514-07 | — | — | 0.887 |
| 3 | MNG1215 | — | — | 0.885 |
| 4 | SRR934862 | — | — | 0.874 |
| 5 | TCGA-CN-4734-01A-01R-1436-07 | — | — | 0.872 |
| 6 | SRR934811 | — | — | 0.867 |
| 7 | 7E4D42B3-FD9B-4184-A4A0-E52E45259428 | — | — | 0.863 |
| 8 | TCGA-UY-A9PA-01A-11R-A38B-07 | — | — | 0.859 |
| 9 | TCGA-CR-7395-01A-11R-2016-07 | — | — | 0.859 |
| 10 | BS_7H4RFCW9 | low-grade glioma | — | 0.857 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 39 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.650 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.630 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.580 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.470 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.440 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| APOPTOSIS | 0.430 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.420 | Idelalisib | — uncovered |
| COMPLEMENT | 0.420 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.420 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.410 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.400 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.380 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.380 | Inavolisib | — uncovered |
| HYPOXIA | 0.350 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.330 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |